These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2028244

  • 21. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G.
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [Abstract] [Full Text] [Related]

  • 22. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D, Samur M, Pamir A, Sencan O, Akbulut H, Yalçin B, Onur H, Demirkazik A, Senler FC, Içli F.
    Cancer; 2000 May 01; 88(9):2033-6. PubMed ID: 10813713
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG.
    Cancer Res; 1993 Dec 15; 53(24):5929-33. PubMed ID: 8261405
    [Abstract] [Full Text] [Related]

  • 26. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H, Nakchbandi V, Chatzisavvidis I, von Voigt C.
    Hepatogastroenterology; 2003 Dec 15; 50(54):1919-26. PubMed ID: 14696433
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Recombinant human GM-CSF: present clinical results and potential use in oncologic and hematologic disorders.
    Jones TC.
    Bull Cancer; 1991 Dec 15; 78(12):1155-9. PubMed ID: 1786428
    [Abstract] [Full Text] [Related]

  • 29. Granulocyte-macrophage colony stimulating factor (rh-GM-CSF) in the treatment of chemotherapy-induced neutropenia.
    Gözdasoglu S, Unal E, Yavuz G, Pamir A, Reisli I, Deda G, Tarcan A, Babacan E, Cavdar AO.
    J Chemother; 1995 Oct 15; 7(5):467-9. PubMed ID: 8596135
    [Abstract] [Full Text] [Related]

  • 30. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R, Talpaz M, Gutterman JU.
    Am J Med; 1992 Jul 15; 93(1):41-8. PubMed ID: 1626572
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA, Vellenga E, de Vries EG, Löwenberg B, Stoter GJ, Rutten FF.
    Pharmacoeconomics; 1997 Sep 15; 12(3):351-60. PubMed ID: 10170460
    [Abstract] [Full Text] [Related]

  • 33. Use of granulocyte-macrophage colony stimulating factor in the treatment of prolonged haematopoietic dysfunction after chemotherapy alone or chemotherapy plus bone marrow transplantation.
    Dierdorf R, Kreuter U, Jones TC.
    Med Oncol; 1997 Jun 15; 14(2):91-8. PubMed ID: 9330268
    [Abstract] [Full Text] [Related]

  • 34. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia.
    Gradishar WJ, Le Beau MM, O'Laughlin R, Vardiman JW, Larson RA.
    Blood; 1992 Nov 15; 80(10):2463-70. PubMed ID: 1421369
    [Abstract] [Full Text] [Related]

  • 35. Southwestern Internal Medicine Conference: clinical use of hematopoietic growth factors.
    Fleischman RA.
    Am J Med Sci; 1993 Apr 15; 305(4):248-73. PubMed ID: 7682752
    [Abstract] [Full Text] [Related]

  • 36. Recombinant human granulocyte-macrophage colony-stimulating factor in acquired or chemotherapy-induced neutropenia. An open clinical trial.
    Piguet D, Chapuis B.
    Acta Oncol; 1994 Apr 15; 33(6):639-43. PubMed ID: 7946441
    [Abstract] [Full Text] [Related]

  • 37. Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia.
    Hord JD, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, Lukens JN.
    J Pediatr Hematol Oncol; 1995 May 15; 17(2):140-4. PubMed ID: 7749763
    [Abstract] [Full Text] [Related]

  • 38. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia.
    Nissen C, Tichelli A, Gratwohl A, Speck B, Milne A, Gordon-Smith EC, Schaedelin J.
    Blood; 1988 Dec 15; 72(6):2045-7. PubMed ID: 3264196
    [Abstract] [Full Text] [Related]

  • 39. Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors.
    van Pelt LJ, de Craen AJ, Langeveld NE, Weening RS.
    Pediatr Hematol Oncol; 1997 Dec 15; 14(6):539-45. PubMed ID: 9383806
    [Abstract] [Full Text] [Related]

  • 40. [Granulocyte and macrophage colony stimulating factor (GM-CSF) in patients with acquired immunodeficiency syndrome and neutropenia].
    Martos A, Domínguez MA, Martínez Lacasa J, Podzamczer D.
    Med Clin (Barc); 1992 Jun 27; 99(5):196-7. PubMed ID: 1507903
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.